Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Akari Therapeutics PLC is a biotechnology business based in the US. Akari Therapeutics shares (AKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Akari Therapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $0.56 |
|---|---|
| 52-week range | $0.54 - $1.83 |
| 50-day moving average | $1.10 |
| 200-day moving average | $1.21 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.41 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.5591 from 2022-09-27
| 1 week (2022-09-21) | -9.53% |
|---|---|
| 1 month (2022-08-26) | -53.02% |
| 3 months (2022-06-28) | -41.46% |
| 6 months (2022-03-28) | -54.91% |
| 1 year (2021-09-28) | -66.92% |
|---|---|
| 2 years (2020-09-28) | -67.11% |
| 3 years (2019-09-27) | 1.69 |
| 5 years (2017-09-28) | 6.31 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -77.44% |
| Return on equity TTM | -187.62% |
| Profit margin | 0% |
| Book value | $0.24 |
| Market capitalisation | $35.6 million |
TTM: trailing 12 months
We're not expecting Akari Therapeutics to pay a dividend over the next 12 months.
Akari Therapeutics's shares were split on a 1:10 basis on 16 September 2015. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Akari Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Akari Therapeutics shares which in turn could have impacted Akari Therapeutics's share price.
Over the last 12 months, Akari Therapeutics's shares have ranged in value from as little as $0.54 up to $1.829. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akari Therapeutics's is 1.2369. This would suggest that Akari Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.